Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors

Isamu Okamoto, Hiroyasu Kaneda, Taroh Satoh, Wataru Okamoto, Masaki Miyazaki, Ryotaro Morinaga, Shinya Ueda, Masaaki Terashima, Asuka Tsuya, Akiko Sarashina, Koichi Konishi, Tokuzo Arao, Kazuto Nishio, Rolf Kaiser, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

BIBF 1120 is an oral multitargeted tyrosine kinase inhibitor that blocks the activity of vascular endothelial growth factor (VEGF) and other growth factor receptors. We have done a phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamic biomarkers of BIBF 1120. Patients with advanced refractory solid tumors were treated with BIBF 1120 at oral doses of 150 to 250 mg twice daily. Drug safety and pharmacokinetics were evaluated, as were baseline and post-treatment levels of circulating CD117-positive bone marrow-derived progenitor cells and plasma soluble VEGF receptor 2 as potential biomarkers for BIBF 1120. Twenty-one patients were treated at BIBF 1120 doses of 150 (n = 3), 200 (n = 12), or 250 mg twice daily (n = 6). Dose-limiting toxicities of reversible grade 3 or 4 elevations of liver enzymes occurred in 3 of 12 patients at 200 mg twice daily and 3 of 6 patients at 250 mg twice daily. Stable disease was achieved in 16 (76.2%) patients, and median progression-free survival was 113 days (95% confidence interval, 77-119 d). Pharmacokinetic analysis indicated that the maximum plasma concentration and area under the curve for BIBF 1120 increased with the dose within the dose range tested. Levels of CD117-positive bone marrow-derived progenitors and soluble VEGF receptor 2 decreased significantly during treatment over all BIBF 1120 dose cohorts. In conclusion, the maximum tolerated dose of BIBF 1120 in the current study was determined to be 200 mg twice daily, and our biomarker analysis indicated that this angiokinase inhibitor is biologically active.

Original languageEnglish
Pages (from-to)2825-2833
Number of pages9
JournalMolecular Cancer Therapeutics
Volume9
Issue number10
DOIs
Publication statusPublished - Oct 1 2010

Fingerprint

Protein-Tyrosine Kinases
Pharmacokinetics
Biomarkers
Safety
Neoplasms
Vascular Endothelial Growth Factor Receptor-2
Bone Marrow
Maximum Tolerated Dose
Growth Factor Receptors
nintedanib
Vascular Endothelial Growth Factor A
Disease-Free Survival
Area Under Curve
Stem Cells
Confidence Intervals
Liver
Enzymes
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. / Okamoto, Isamu; Kaneda, Hiroyasu; Satoh, Taroh; Okamoto, Wataru; Miyazaki, Masaki; Morinaga, Ryotaro; Ueda, Shinya; Terashima, Masaaki; Tsuya, Asuka; Sarashina, Akiko; Konishi, Koichi; Arao, Tokuzo; Nishio, Kazuto; Kaiser, Rolf; Nakagawa, Kazuhiko.

In: Molecular Cancer Therapeutics, Vol. 9, No. 10, 01.10.2010, p. 2825-2833.

Research output: Contribution to journalArticle

Okamoto, I, Kaneda, H, Satoh, T, Okamoto, W, Miyazaki, M, Morinaga, R, Ueda, S, Terashima, M, Tsuya, A, Sarashina, A, Konishi, K, Arao, T, Nishio, K, Kaiser, R & Nakagawa, K 2010, 'Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors', Molecular Cancer Therapeutics, vol. 9, no. 10, pp. 2825-2833. https://doi.org/10.1158/1535-7163.MCT-10-0379
Okamoto, Isamu ; Kaneda, Hiroyasu ; Satoh, Taroh ; Okamoto, Wataru ; Miyazaki, Masaki ; Morinaga, Ryotaro ; Ueda, Shinya ; Terashima, Masaaki ; Tsuya, Asuka ; Sarashina, Akiko ; Konishi, Koichi ; Arao, Tokuzo ; Nishio, Kazuto ; Kaiser, Rolf ; Nakagawa, Kazuhiko. / Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 10. pp. 2825-2833.
@article{37a75e7ac91e4d00a43368291eb912e9,
title = "Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors",
abstract = "BIBF 1120 is an oral multitargeted tyrosine kinase inhibitor that blocks the activity of vascular endothelial growth factor (VEGF) and other growth factor receptors. We have done a phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamic biomarkers of BIBF 1120. Patients with advanced refractory solid tumors were treated with BIBF 1120 at oral doses of 150 to 250 mg twice daily. Drug safety and pharmacokinetics were evaluated, as were baseline and post-treatment levels of circulating CD117-positive bone marrow-derived progenitor cells and plasma soluble VEGF receptor 2 as potential biomarkers for BIBF 1120. Twenty-one patients were treated at BIBF 1120 doses of 150 (n = 3), 200 (n = 12), or 250 mg twice daily (n = 6). Dose-limiting toxicities of reversible grade 3 or 4 elevations of liver enzymes occurred in 3 of 12 patients at 200 mg twice daily and 3 of 6 patients at 250 mg twice daily. Stable disease was achieved in 16 (76.2{\%}) patients, and median progression-free survival was 113 days (95{\%} confidence interval, 77-119 d). Pharmacokinetic analysis indicated that the maximum plasma concentration and area under the curve for BIBF 1120 increased with the dose within the dose range tested. Levels of CD117-positive bone marrow-derived progenitors and soluble VEGF receptor 2 decreased significantly during treatment over all BIBF 1120 dose cohorts. In conclusion, the maximum tolerated dose of BIBF 1120 in the current study was determined to be 200 mg twice daily, and our biomarker analysis indicated that this angiokinase inhibitor is biologically active.",
author = "Isamu Okamoto and Hiroyasu Kaneda and Taroh Satoh and Wataru Okamoto and Masaki Miyazaki and Ryotaro Morinaga and Shinya Ueda and Masaaki Terashima and Asuka Tsuya and Akiko Sarashina and Koichi Konishi and Tokuzo Arao and Kazuto Nishio and Rolf Kaiser and Kazuhiko Nakagawa",
year = "2010",
month = "10",
day = "1",
doi = "10.1158/1535-7163.MCT-10-0379",
language = "English",
volume = "9",
pages = "2825--2833",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors

AU - Okamoto, Isamu

AU - Kaneda, Hiroyasu

AU - Satoh, Taroh

AU - Okamoto, Wataru

AU - Miyazaki, Masaki

AU - Morinaga, Ryotaro

AU - Ueda, Shinya

AU - Terashima, Masaaki

AU - Tsuya, Asuka

AU - Sarashina, Akiko

AU - Konishi, Koichi

AU - Arao, Tokuzo

AU - Nishio, Kazuto

AU - Kaiser, Rolf

AU - Nakagawa, Kazuhiko

PY - 2010/10/1

Y1 - 2010/10/1

N2 - BIBF 1120 is an oral multitargeted tyrosine kinase inhibitor that blocks the activity of vascular endothelial growth factor (VEGF) and other growth factor receptors. We have done a phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamic biomarkers of BIBF 1120. Patients with advanced refractory solid tumors were treated with BIBF 1120 at oral doses of 150 to 250 mg twice daily. Drug safety and pharmacokinetics were evaluated, as were baseline and post-treatment levels of circulating CD117-positive bone marrow-derived progenitor cells and plasma soluble VEGF receptor 2 as potential biomarkers for BIBF 1120. Twenty-one patients were treated at BIBF 1120 doses of 150 (n = 3), 200 (n = 12), or 250 mg twice daily (n = 6). Dose-limiting toxicities of reversible grade 3 or 4 elevations of liver enzymes occurred in 3 of 12 patients at 200 mg twice daily and 3 of 6 patients at 250 mg twice daily. Stable disease was achieved in 16 (76.2%) patients, and median progression-free survival was 113 days (95% confidence interval, 77-119 d). Pharmacokinetic analysis indicated that the maximum plasma concentration and area under the curve for BIBF 1120 increased with the dose within the dose range tested. Levels of CD117-positive bone marrow-derived progenitors and soluble VEGF receptor 2 decreased significantly during treatment over all BIBF 1120 dose cohorts. In conclusion, the maximum tolerated dose of BIBF 1120 in the current study was determined to be 200 mg twice daily, and our biomarker analysis indicated that this angiokinase inhibitor is biologically active.

AB - BIBF 1120 is an oral multitargeted tyrosine kinase inhibitor that blocks the activity of vascular endothelial growth factor (VEGF) and other growth factor receptors. We have done a phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamic biomarkers of BIBF 1120. Patients with advanced refractory solid tumors were treated with BIBF 1120 at oral doses of 150 to 250 mg twice daily. Drug safety and pharmacokinetics were evaluated, as were baseline and post-treatment levels of circulating CD117-positive bone marrow-derived progenitor cells and plasma soluble VEGF receptor 2 as potential biomarkers for BIBF 1120. Twenty-one patients were treated at BIBF 1120 doses of 150 (n = 3), 200 (n = 12), or 250 mg twice daily (n = 6). Dose-limiting toxicities of reversible grade 3 or 4 elevations of liver enzymes occurred in 3 of 12 patients at 200 mg twice daily and 3 of 6 patients at 250 mg twice daily. Stable disease was achieved in 16 (76.2%) patients, and median progression-free survival was 113 days (95% confidence interval, 77-119 d). Pharmacokinetic analysis indicated that the maximum plasma concentration and area under the curve for BIBF 1120 increased with the dose within the dose range tested. Levels of CD117-positive bone marrow-derived progenitors and soluble VEGF receptor 2 decreased significantly during treatment over all BIBF 1120 dose cohorts. In conclusion, the maximum tolerated dose of BIBF 1120 in the current study was determined to be 200 mg twice daily, and our biomarker analysis indicated that this angiokinase inhibitor is biologically active.

UR - http://www.scopus.com/inward/record.url?scp=77958038695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958038695&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0379

DO - 10.1158/1535-7163.MCT-10-0379

M3 - Article

VL - 9

SP - 2825

EP - 2833

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -